Form 4: Axsome Therapeutics Director Receives RSU Grant

Director Roger Jeffs was granted 1,721 restricted stock units as part of an equity compensation arrangement.

Summary

• Director Roger Jeffs received a grant of 1,721 restricted stock units (RSUs) on June 5, 2026.
• Each RSU represents a contingent right to receive one share of Axsome Therapeutics common stock.
• The grant is subject to a one-year vesting schedule, fully vesting on June 5, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shareholders upon the eventual vesting and issuance of common stock.

Risks

• Market volatility affecting the future value of the underlying common stock.

Future Outlook

The RSUs will vest in full on the one-year anniversary of the grant date, June 5, 2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant size and one-year cliff vesting schedule are consistent with standard compensation practices for mid-cap biotechnology companies.

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the equity grant.

Next Steps

• Vesting of 1,721 RSUs on June 5, 2027.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation